New mRNA flu vaccine shows promise in early human trial
NCT ID NCT06602531
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza. 212 healthy adults aged 18-80 received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus placebo. Researchers monitored safety and immune responses to find the best dose and schedule for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Self-amplifying mRNA pandemic influenza vaccine (ARCT-2304)
- What this could lead to
- If successful, this could lead to a faster, more effective vaccine against pandemic influenza strains.
- What could go wrong
- This is an early phase 1 trial with only 212 participants, so safety and immune response are still being explored. The vaccine may not produce strong enough immunity or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States
-
Tekton Research
Longmont, Colorado, 80501, United States
-
Velocity Clinical Research
La Mesa, California, 91942, United States
-
Velocity Clinical Research
San Bernardino, California, 92408, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lab-made flu vaccine outperform the traditional egg-based shot?
- Bedside flu shot for heart patients: a simple strategy to save lives?
- New hope for tiniest flu patients: IV zanamivir tested in infants under 6 months
- New adjuvanted flu vaccine aims to boost protection in older adults
- New rapid test could spot flu and RSV in minutes at your local clinic
- Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV